MDMA Reimbursement Conference Notes: 2015

Perspectives on Medical Reimbursement By JR Associates For years, our consultants have been featured speakers at the MDMA Annual Coverage, Reimbursement & Health Policy Conference — and the 2015 conference was no exception. Our Founder and President, Judy Rosenbloom, teamed with VP Health Policy, Jo Ellen Slurzberg, to share their expertise with the medical device manufacturing community in…

Read More »

Medical Device Coverage: Do Private Payers Follow Medicare’s Lead?

Perspectives on Medical Reimbursement By JR Associates When making decisions about medical device coverage, do private insurers take their cues from Medicare (CMS)? Not necessarily, according to a recent study published in the peer-review journal, Health Affairs. According to the research abstract, an analysis of CMS national coverage decisions (NCDs) revealed that: ~50% were equivalent to corresponding private payer policies ~25% were…

Read More »

What Should Life Sciences Startups Know About Reimbursement?

Reimbursement for Life Sciences Startups - JR Assocates VP Global Health Policy Jo Ellen Surzberg at Harvard Innovation Lab

Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…

Read More »

How Can Medical Innovators Build a Case for Reimbursement?

Perspectives on Medical Reimbursement By JR Associates Coverage. Coding. Payment. These three factors deeply influence reimbursement for every new medical technology product. But there are no “cookie cutter” solutions. Because the reimbursement landscape is so complex and time consuming, it’s smart to start preparing for reimbursement as early as possible in the business planning and product development process. But…

Read More »

Autism Investment Conference Session Notes

Jo Ellen Slurzberg_Reimbursement Strategies Autism Investment Conference

Perspectives on Medical Reimbursement By JR Associates Continuing its efforts to cultivate a marketplace of innovation that better serves those affected by autism, Autism Speaks recently hosted its third annual Autism Investment Conference in Boston. Our VP of Global Health Policy, Jo Ellen Slurzberg, was among the nearly 200 investors, entrepreneurs, healthcare advocates and corporate…

Read More »

Reimbursement Strategy: Extending Product Reach Across Multiple Markets

How can medical technology innovators leverage reimbursement strategy across markets? Advice from JR Associates consultants

Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…

Read More »

Bundled Payments: Implications for Medical Device & Drug/Biologic Companies

Bundled Payments for Medical Technology

Perspectives on Medical Reimbursement By JR Associates Recently, the trade press and mainstream news have been paying a lot of attention to bundled payments. Stories have focused primarily on how this shift in medical reimbursement will affect patients, providers and payers. Payers and provider networks are creating internal systems to identify the cost of treating…

Read More »

Proposed Changes In MPFS IDE Clinical Trial Coverage Rule: Comments to CMS

Perspectives on Medicare Policies By JR Associates SUBJECT: Medicare Physician Fee Schedule Rule: Proposed Changes for the Process for Covering Items and Services in an Investigational Device Exemption (IDE), Centers for Medicare and Medicaid Services (CMS) 78 Fed. Reg. 43282, 43342-47, 43523-25 (July 19, 2013) OVERVIEW: JR Associates is concerned about CMS’ proposed changes to…

Read More »